{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:46:29Z","timestamp":1774395989758,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clinre.2021.101778","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T06:59:07Z","timestamp":1627541947000},"page":"101778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immune checkpoint inhibitor induced colitis: A nationwide population-based study"],"prefix":"10.1016","volume":"46","author":[{"given":"Natalie","family":"Farha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7603-8705","authenticated-orcid":false,"given":"Motasem","family":"Alkhayyat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohannad Abou","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinre.2021.101778_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.clinre.2021.101778_bib0002","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","article-title":"Checkpoint blocking antibodies in cancer immunotherapy","volume":"588","author":"Kyi","year":"2014","journal-title":"FEBS Lett"},{"issue":"3","key":"10.1016\/j.clinre.2021.101778_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/107327481402100308","article-title":"PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy","volume":"21","author":"Dolan","year":"2014","journal-title":"Cancer Control"},{"issue":"20","key":"10.1016\/j.clinre.2021.101778_bib0004","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Asaoka","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clinre.2021.101778_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinre.2021.101778_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"10.1016\/j.clinre.2021.101778_bib0007","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune checkpoint inhibitor-associated colitis and hepatitis [published correction appears in Clin Transl Gastroenterol. 2018 Nov 14;9(11):206. Title corrected]","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2021.101778_bib0008","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): results of a Retrospective Study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"issue":"4","key":"10.1016\/j.clinre.2021.101778_bib0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.clinre.2021.101778_bib0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clinre.2021.101778_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819884196","article-title":"Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management","volume":"12","author":"Shivaji","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.clinre.2021.101778_bib0012","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1990"},{"key":"10.1016\/j.clinre.2021.101778_bib0013a","series-title":"IBM SPSS Statistics for Windows, Version 25.0","year":"2017"},{"key":"10.1016\/j.clinre.2021.101778_bib0014","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?","volume":"14","author":"Robert","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.clinre.2021.101778_bib0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","article-title":"Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management","volume":"37","author":"Kaehler","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinre.2021.101778_bib0016","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/PAS.0b013e31817150e3","article-title":"Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis","volume":"32","author":"Oble","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"10.1016\/j.clinre.2021.101778_bib0017","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinre.2021.101778_bib0018","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 Inhibitors in cancer patients [published correction appears in Cancer Immunol Res. 2018 Apr;6(4):498-499]","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.clinre.2021.101778_bib0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2011.29.15_suppl.8583","article-title":"Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma [abstract]","volume":"29","author":"Ibrahim","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2021.101778_bib0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/09546634.2013.813897","article-title":"Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2","volume":"25","author":"Ma","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.clinre.2021.101778_bib0021","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.3747\/co.27.6251","article-title":"The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"27","author":"Bishay","year":"2020","journal-title":"Curr Oncol"},{"issue":"15","key":"10.1016\/j.clinre.2021.101778_bib0022","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2021.101778_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clinre.2021.101778_bib0024","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clinre.2021.101778_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol."},{"issue":"1","key":"10.1016\/j.clinre.2021.101778_bib0026","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"35","key":"10.1016\/j.clinre.2021.101778_bib0027","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.3748\/wjg.v22.i35.7868","article-title":"Interaction of obesity and inflammatory bowel disease","volume":"22","author":"Harper","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.clinre.2021.101778_bib0028","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clinre.2021.101778_bib0029","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00590-014-1423-2","article-title":"Validation study of a pooled electronic healthcare database: the effect of obesity on the revision rate of total knee arthroplasty","volume":"24","author":"Pfeferle","year":"2014","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"10.1016\/j.clinre.2021.101778_bib0030","series-title":"2018 IEEE 38th International Conference on Distributed Computing Systems (ICDCS)","first-page":"1238","article-title":"A trusted healthcare data analytics cloud platform","author":"Iyengar","year":"2018"},{"key":"10.1016\/j.clinre.2021.101778_bib0031","article-title":"Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: A Cohort Study","author":"Khoudari","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2021.101778_bib0032","first-page":"izaa252","article-title":"Lower rates of colorectal cancer in patients with inflammatory bowel disease using anti-TNF therapy","author":"Alkhayyat","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinre.2021.101778_bib0033","article-title":"Pancreatic manifestations in rheumatoid arthritis: a national population-based study","author":"Alkhayyat","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.clinre.2021.101778_bib0034","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/MPA.0000000000001659","article-title":"The epidemiology of pancreatic cancer and the association with acetylsalicylic acid in the United States: a population-based study","volume":"49","author":"Khoudari","year":"2020","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.clinre.2021.101778_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MPA.0000000000001721","article-title":"Prevalence of myocardial infarction in patients with chronic pancreatitis","volume":"50","author":"Khan","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.clinre.2021.101778_bib0036","article-title":"The risk of acute and chronic pancreatitis in celiac disease","author":"Alkhayyat","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.clinre.2021.101778_bib0037","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MPA.0000000000001538","article-title":"The risk of vitamin D deficiency, osteoporosis, and fractures in acute pancreatitis","volume":"49","author":"Abou Saleh","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.clinre.2021.101778_bib0038","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/jamia.2009.001057","article-title":"Migrating existing clinical content from ICD-9 to SNOMED","volume":"17","author":"Nadkarni","year":"2010","journal-title":"J Am Med Inform Assoc JAMIA"},{"issue":"9","key":"10.1016\/j.clinre.2021.101778_bib0039","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1200\/JOP.19.00672","article-title":"Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis","volume":"16","author":"Grover","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.clinre.2021.101778_bib0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121001571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121001571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T20:10:00Z","timestamp":1728072600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740121001571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2210740121001571"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101778","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor induced colitis: A nationwide population-based study","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101778"}}